Suramin inhibits renal fibrosis in chronic kidney disease

Journal of the American Society of Nephrology

Volumn 22, Issue 6, 2011, Pages 1064-1075

  Liu, Na ^a,b   Tolbert, Evelyn ^a   Pang, Maoyin ^a   Ponnusamy, Murugavel ^a   Yan, Haidong ^b   Zhuang, Shougang ^a,b  

^a BROWN UNIVERSITY   (United States)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; CREATININE; FIBRONECTIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SURAMIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL INFILTRATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; EXTRACELLULAR MATRIX; FIBROBLAST; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY TUBULE DAMAGE; LEUKOCYTE; MALE; MOUSE; NONHUMAN; OBSTRUCTIVE NEPHROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEINURIA; RAT; RENAL PROTECTION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

EID: 79957768354     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2010090956     Document Type: Article

References (54)

1. Wynn TA: Cellular and molecular mechanisms of fibrosis. J Pathol 214: 199-210, 2008
2. Neilson EG: Mechanisms of disease: Fibroblasts - A new look at an old problem. Nat Clin Pract Nephrol 2: 101-108, 2006
3. Lin SL, Kisseleva T, Brenner DA, Duffield JS: Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 173: 1617-1627, 2008
4. Boor P, Ostendorf T, Floege J: Renal fibrosis: Novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 6: 643-656, 2010
5. Grande MT, Lopez-Novoa JM: Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat Rev Nephrol 5: 319-328, 2009
6. Misseri R, Rink RC, Meldrum DR, Meldrum KK: Inflammatory mediators and growth factors in obstructive renal injury. J Surg Res 119: 149-159, 2004 (Pubitemid 38625641)
7. Misseri R, Meldrum KK: Mediators of fibrosis and apoptosis in obstructive uropathies. Curr Urol Rep 6: 140-145, 2005
8. Couser WG, Johnson RJ: Mechanisms of progressive renal disease in glomerulonephritis. Am J Kidney Dis 23: 193-198, 1994 (Pubitemid 24075310)
9. Floege J, Eitner F, Alpers CE: A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol 19: 12-23, 2008
10. Eddy AA: Molecular basis of renal fibrosis. Pediatr Nephrol 15: 290-301, 2000
11. Bottinger EP: TGF-beta in renal injury and disease. Semin Nephrol 27: 309-320, 2007
12. Liu Y: Renal fibrosis: New insights into the pathogenesis and therapeutics. Kidney Int 69: 213-217, 2006
13. Wang W, Koka V, Lan HY: Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology (Carlton) 10: 48-56, 2005 (Pubitemid 40349406)
14. Song CY, Kim BC, Hong HK, Lee HS: TGF-beta type II receptor deficiency prevents renal injury via decrease in ERK activity in crescentic glomerulonephritis. Kidney Int 71: 882-888, 2007 (Pubitemid 46663790)
15. Pat B, Yang T, Kong C, Watters D, Johnson DW, Gobe G: Activation of ERK in renal fibrosis after unilateral ureteral obstruction: Modulation by antioxidants. Kidney Int 67: 931-943, 2005 (Pubitemid 41623317)
16. Terzi F, Burtin M, Hekmati M, Federici P, Grimber G, Briand P, Friedlander G: Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulo-interstitial lesions after renal injury. J Clin Invest 106: 225-234, 2000 (Pubitemid 30483126)
17. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, Terzi F: Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: A new therapeutic approach. Nat Med 11: 867-874, 2005 (Pubitemid 41161119)
18. Ludewig D, Kosmehl H, Sommer M, Bohmer FD, Stein G: PDGF receptor kinase blocker AG1295 attenuates interstitial fibrosis in rat kidney after unilateral obstruction. Cell Tissue Res 299: 97-103, 2000 (Pubitemid 30028726)
19. Bonner JC: Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 15: 255-273, 2004
20. Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y, Abbruzzese JL, Hortobagyi GN, Hung MC: Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 67: 9066-9076, 2007 (Pubitemid 47535891)
21. Vignais ML, Sadowski HB, Watling D, Rogers NC, Gilman M: Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins. Mol Cell Biol 16: 1759-1769, 1996 (Pubitemid 26095648)
22. Pang M, Ma L, Gong R, Tolbert E, Mao H, Ponnusamy M, Chin YE, Yan H, Dworkin LD, Zhuang S: A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int 78: 257-268, 2010
23. Flamant M, Tharaux PL, Placier S, Henrion D, Coffman T, Chatziantoniou C Dussaule JC: Epidermal growth factor receptor trans-activation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice. FASEB J 17: 327-329, 2003
24. Coffey RJ Jr, Leof EB, Shipley GD, Moses HL: Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J Cell Physiol 132: 143-148, 1987 (Pubitemid 17105335)
25. Kloen P, Jennings CL, Gebhardt MC, Springfield DS, Mankin HJ: Suramin inhibits growth and transforming growth factor-beta 1 (TGF-beta 1) binding in osteosarcoma cell lines. Eur J Cancer 30A: 678-682, 1994 (Pubitemid 24164259)
26. Fujiuchi S, Ohsaki Y, Kikuchi K: Suramin inhibits the growth of nonsmall- cell lung cancer cells that express the epidermal growth factor receptor. Oncology 54: 134-140, 1997 (Pubitemid 27101761)
27. Abdiu A, Larsson SE, Wasteson A, Walz TM: Suramin blocks growthstimulatory effects of platelet-derived growth factor on malignant fibrous histiocytomas in vitro. Cancer Lett 146: 189-194, 1999 (Pubitemid 29492889)
28. Stein CA, LaRocca RV, Thomas R, McAtee N, Myers CE: Suramin: An anticancer drug with a unique mechanism of action. J Clin Oncol 7: 499-508, 1989 (Pubitemid 19098145)
29. Zumkeller W, Schofield PN: Growth factors, cytokines and soluble forms of receptor molecules in cancer patients. Anticancer Res 15: 343-348, 1995
30. Stein CA: Suramin: A novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 53: 2239-2248, 1993
31. Vogelzang NJ, Karrison, T, Stadler WM, Garcia J, Cohn H, Kugler J, Troeger T, Giannone L, Arrieta R, Ratain MJ, Vokes EE: A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. Cancer 100: 65-71, 2004 (Pubitemid 37553540)
32. Woll PJ, Ranson M, Margison J, Thomson Y, van der Water L, George N, Howell A: Suramin for breast and prostate cancer: A pilot study of intermittent short infusions without adaptive control. Ann Oncol 5: 597-600, 1994 (Pubitemid 24283095)
33. Chan YS, Li Y, Foster W, Horaguchi T, Somogyi G, Fu FH, Huard J: Antifibrotic effects of suramin in injured skeletal muscle after laceration. J Appl Physiol 95: 771-780, 2003 (Pubitemid 36944303)
34. Li C, Jiang X, Yang L, Liu X, Yue S, Li L: Involvement of sphingosine 1-phosphate (SIP)/S1P3 signaling in cholestasis-induced liver fibrosis. Am J Pathol 175: 1464-1472, 2009
35. McNally WP, DeHart PD, Lathia C, Whitfield LR: Distribution of [14C]suramin in tissues of male rats following a single intravenous dose. Life Sci 67: 1847-1857, 2000
36. Bhogal RK, Stoica CM, McGaha TL, Bona CA: Molecular aspects of regulation of collagen gene expression in fibrosis. J Clin Immunol 25: 592-603, 2005 (Pubitemid 43011750)
37. Kaminska B, Wesolowska A, Danilkiewicz M: TGF beta signalling and its role in tumour pathogenesis. Acta Biochim Pol 52: 329-337, 2005 (Pubitemid 41133768)
38. Bani-Hani AH, Campbell MT, Meldrum DR, Meldrum KK: Cytokines in epithelial-mesenchymal transition: A new insight into obstructive nephropathy. J Urol 180: 461-468, 2008
39. Jodrell DI, Reyno LM, Sridhara R, Eisenberger MA, Tkaczuk KH, Zuhowski EG, Sinibaldi VJ, Novak MJ, Egorin MJ: Suramin: Development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. J Clin Oncol 12: 166-175, 1994 (Pubitemid 24020637)
40. Eisenberger MA, Reyno LM: Suramin. Cancer Treat Rev 20: 259-273, 1994 (Pubitemid 24213089)
41. Tang WW, Ulich TR, Lacey DL, Hill DC, Qi M, Kaufman SA, Van GY, Tarpley JE, Yee JS: Platelet-derived growth factor-BB induces renal tubulointerstitial myofibroblast formation and tubulointerstitial fibrosis. Am J Pathol 148: 1169-1180, 1996 (Pubitemid 26108254)
42. Phillips AO, Steadman R, Topley N, Williams JD: Elevated D-glucose concentrations modulate TGF-beta 1 synthesis by human cultured renal proximal tubular cells. The permissive role of platelet-derived growth factor. Am J Pathol 147: 362-374, 1995
43. Dranoff JA, Kruglov EA, Abreu-Lanfranco O, Nguyen T, Arora G, Jain D: Prevention of liver fibrosis by the purinoceptor antagonist pyridoxal-phosphate- 6-azophenyl-2′,4′-disulfonate (PPADS). In Vivo 21: 957-965, 2007
44. Goncalves RG, Gabrich L, Rosario A Jr, Takiya CM, Ferreira ML, Chiarini LB, Persechini PM, Coutinho-Silva R, Leite, M Jr: The role of purinergic P2X7 receptors in the inflammation and fibrosis of unilateral ureteral obstruction in mice. Kidney Int 70: 1599-1606, 2006 (Pubitemid 44606995)
45. Xin C, Ren S, Kleuser B, Shabahang S, Eberhardt W, Radeke H, Schafer-Korting M, Pfeilschifter J, Huwiler A: Sphingosine 1-phosphate cross-activates the Smad signaling cascade and mimics transforming growth factor-beta-induced cell responses. J Biol Chem 279: 35255-35262, 2004 (Pubitemid 39100522)
46. Border WA, Noble NA: TGF-beta in kidney fibrosis: A target for gene therapy. Kidney Int 51: 1388-1396, 1997 (Pubitemid 27239888)
47. Tamaki K, Okuda S: Role of TGF-beta in the progression of renal fibrosis. Contrib Nephrol 139: 44-65, 2003
48. Ogata H, Chinen T, Yoshida T, Kinjyo I, Takaesu G, Shiraishi H, Iida M, Kobayashi T, Yoshimura A: Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta1 production. Oncogene 25: 2520-2530, 2006
49. Rodriguez-Pena AB, Grande MT, Eleno N, Arevalo M, Guerrero C, Santos E, Lopez-Novoa JM: Activation of Erk1/2 and Akt following unilateral ureteral obstruction. Kidney Int 74: 196-209, 2008 (Pubitemid 351915085)
50. Kaur M, Reed E, Sartor O, Dahut W, Figg WD: Suramin's development: What did we learn? Invest New Drugs 20: 209-219, 2002
51. Zhang Y, Song S, Yang F, Au JL, Wientjes MG: Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. J Pharmacol Exp Ther 299: 426-433, 2001 (Pubitemid 32979652)
52. Lam ET, Au JL, Otterson GA, Guillaume Wientjes M, Chen L, Shen T, Wei Y, Li X, Bekaii-Saab T, Murgo AJ, Jensen RR, Grever M, Villalona- Calero, MA: Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. Cancer Chemother Pharmacol 66: 1019-1029, 2010
53. Pang M, Kothapally J, Mao H, Tolbert E, Ponnusamy M, Chin YE, Zhuang S: Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 297: F996-F1005, 2009
54. Liu Y, Rajur K, Tolbert E, Dworkin LD: Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways. Kidney Int 58: 2028-2043, 2000